Skip to Content Facebook Feature Image

Amprius Ships High-Performance SiCore Cells to Multiple Drone Customers from U.S. Pilot Line

News

Amprius Ships High-Performance SiCore Cells to Multiple Drone Customers from U.S. Pilot Line
News

News

Amprius Ships High-Performance SiCore Cells to Multiple Drone Customers from U.S. Pilot Line

2025-07-22 20:31 Last Updated At:20:51

FREMONT, Calif.--(BUSINESS WIRE)--Jul 22, 2025--

Amprius Technologies, Inc.(“Amprius” or the “Company”) (NYSE: AMPX), a leader in next-generation lithium-ion batteries with its Silicon Anode Platform, today announced it has delivered SiCore ® battery cells to multiple advanced drone and unmanned aerial vehicle (UAV) customers from its Fremont, California pilot line. These cells include 450 Wh/kg high-energy cells to Airbus subsidiary AALTO and balanced energy-and-power cells to drone manufacturers supporting tactical and commercial missions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250722309461/en/

Amprius customer qualification often begins with prototype SiCore cells built at the Company’s Fremont facility, accelerating the transition from development to deployment for advanced applications. Recent examples include deliveries to AALTO and other UAV leaders for high-altitude and tactical drone missions. The newly shipped 450 Wh/kg SiCore cells are engineered to support even longer-duration flights, where energy density and weight are mission-critical.

“Amprius’ SiCore cells represent a major advancement in energy performance, supporting the ultra-lightweight, long-endurance requirements of our high-altitude operations,” said Pierre-Antoine Aubourg, chief technology officer at AALTO. “Their silicon anode technology has already enabled Zephyr to operate in the stratosphere overnight for months at a time, an unprecedented milestone in persistent flight. We look forward to working with Amprius as we qualify their next-generation cells to power the future of Stratospace innovation.”

“We are expanding our pilot production in Fremont to meet a strong increase from leading drone manufacturers,” said Dr. Kang Sun, CEO of Amprius Technologies. “Shipping our industry-leading SiCore cells to AALTO and other leading drone OEMs marks another key milestone in our commercial scale-up. From high-energy HAPS cells to balanced-performance drone batteries, we’re now delivering solutions that meet a wide range of advanced mission needs.”

Amprius’ Fremont headquarters serves as the Company’s center for R&D, prototyping, and pilot-scale production, where the SiCore platform was developed, validated, and transitioned into commercial deployment. This same team led the development of the SiCore 370 Wh/kg High Power cell, designed to deliver exceptional energy and power performance in a compact, mission-ready format.

While Fremont enables rapid development and early-stage production, Amprius is scaling its global supply chain to meet growing commercial demand. The Company has secured more than 1.8 GWh of manufacturing capacity through international contract partnerships, including a strategic agreement in South Korea, to support broader adoption across aerospace, defense, and electric mobility markets.

For more information, please visit the Amprius investor relations website at ir.amprius.com.

About Amprius Technologies, Inc.

Amprius Technologies, Inc. is a leading manufacturer of high-energy and high-power lithium-ion batteries, producing the industry’s highest-known energy density cells. The Company’s commercially available SiCore ® and SiMaxx™ batteries deliver up to 450 Wh/kg and 1,150 Wh/L, with third-party validation of 500 Wh/kg and 1,300 Wh/L. The Company’s corporate headquarters is in Fremont, California, where it maintains an R&D lab and a MWh scale manufacturing facility for the fabrication of silicon anodes and cells. To serve customer demand, Amprius entered into several agreements to secure over 1.8 GWh of contract manufacturing capacity. For additional information, please visit amprius.com. Also, see the Company’s LinkedIn page.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “believe,” “seek” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the performance of Amprius’ products, the benefits of Amprius’ products to its customers and the drone and UAV industry, the potential applications and addressable market of Amprius’ products, the ability of Amprius to expand its Fremont pilot production and enable rapid development and early-stage production, and the ability of Amprius to scale commercially and meet customers’ demand. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Amprius’ management and are not predictions of actual performance. Actual results could differ materially from these forward-looking statements as a result of certain risks and uncertainties. These forward-looking statements are subject to a number of risks and uncertainties, including Amprius’ liquidity position; risks related to the rollout of Amprius’ business and the timing of expected business milestones; Amprius’ ability to commercially produce high performing batteries; the effects of competition on Amprius’ business; supply shortages in the materials necessary for the production of Amprius’ products; and changes in domestic and foreign business, market, financial, political and legal conditions. For more information on these risks and uncertainties that may impact the operations and projections discussed herein can be found in the documents we filed from time to time with the Securities and Exchange Commission (the “SEC”), all of which are available on the SEC’s website atwww.sec.gov. There may be additional risks that Amprius does not presently know or that Amprius currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Amprius’ expectations, plans or forecasts of future events and views as of the date of this press release. These forward-looking statements should not be relied upon as representing Amprius’ assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements. Except as required by law, Amprius specifically disclaims any obligation to update any forward-looking statements.

Amprius ships high-performance SiCore cells to multiple drone customers from U.S. pilot line.

Amprius ships high-performance SiCore cells to multiple drone customers from U.S. pilot line.

LONDON (AP) — King Charles III has been “deeply touched” by the response to his update on his cancer treatment, Buckingham Palace said Saturday, adding that the monarch is pleased to have highlighted the value of screening programs for the disease.

Medics and health charities have praised the king for his openness, saying his statement on Friday had already prompted people to seek information about cancer.

In a strikingly personal video statement, the British monarch acknowledged that a cancer diagnosis can feel “overwhelming,” but said catching the disease early brings “the precious gift of hope.”

Here’s what to know about the king's condition and his message.

The 77-year-old king said in a statement broadcast Friday that his treatment schedule will be reduced in the new year, “thanks to early diagnosis, effective intervention and adherence to ‘doctors’ orders.’”

He encouraged others to take advantage of screening programs such as those for breast, bowel and cervical cancer offered by Britain’s public health service.

“Early diagnosis quite simply saves lives,” the king said in the statement aired during a “Stand Up to Cancer” telethon on TV station Channel 4. He said catching the disease early had allowed him “to continue leading a full and active life even while undergoing treatment.”

Charles has received outpatient treatment for almost two years. Buckingham Palace did not say the king is in remission, but that his treatment is moving to a “precautionary phase” and his condition will be monitored to ensure his continued recovery.

“I know from my own experience that a cancer diagnosis can feel overwhelming,” the king said in his video statement. “Yet I also know that early detection is the key that can transform treatment journeys, giving invaluable time to medical teams – and, to their patients, the precious gift of hope.”

Charles announced in February 2024 that he had been diagnosed with cancer, and, in a break from centuries of secrecy about royal health, he has since spoken about the illness, using his story to promote cancer awareness and treatment.

The openness has limits, though. The king has not disclosed what type of cancer he has or what kind of treatment he is receiving. The palace said it was an intentional decision designed to ensure his message reaches the widest possible audience.

The king’s cancer was discovered after treatment for an enlarged prostate. While doctors ruled out prostate cancer, tests revealed “a separate issue of concern,” palace officials said last year.

Charles suspended his public appearances for about two months after his diagnosis. Since returning to the public eye, he has visited cancer treatment centers across the country and shared stories with fellow patients.

Buckingham Palace said Charles “will be greatly encouraged and deeply touched by the very positive reaction" his message has generated. “He will be particularly pleased at the way it has helped to shine a light on the benefits of cancer screening programs,” it added.

British cancer charities said the number of people seeking information about cancer jumped after the king revealed he was undergoing treatment last year.

Cancer Research U.K. said about 100,000 people have visited its Screening Checker website since it was launched on Dec. 5, most of them since the king’s statement on Friday.

The charity's Chief Executive Michelle Mitchell said: “When public figures speak openly about their cancer diagnosis, it can prompt others to check in on their health.”

Broadcaster Jonathan Dimbleby, the king’s authorized biographer, said the statement was “a remarkable thing for a monarch to do.”

“It takes guts, and the fact that he came out and did that will save lives,’” Dimbleby said.

The Princess of Wales, who announced her own cancer diagnosis six weeks after her father-in-law, has also given updates on her treatment. Kate announced in January that her cancer is in remission.

Find more of AP’s coverage at https://apnews.com/hub/royalty

Britain's King Charles III attends an Advent Service at Westminster Abbey, in London, Wednesday, Dec. 10, 2025. (Chris Jackson/Pool Photo via AP)

Britain's King Charles III attends an Advent Service at Westminster Abbey, in London, Wednesday, Dec. 10, 2025. (Chris Jackson/Pool Photo via AP)

Britain's King Charles III attends an Advent Service at Westminster Abbey, in London, Wednesday, Dec. 10, 2025. (Chris Jackson/Pool Photo via AP)

Britain's King Charles III attends an Advent Service at Westminster Abbey, in London, Wednesday, Dec. 10, 2025. (Chris Jackson/Pool Photo via AP)

Recommended Articles